Copaxone® continued to lead as the number one MS therapy in the U.S. and globally, with record in-market sales of $595 million in the fourth quarter of 2008, an increase of 37% over the fourth quarter of 2007. In the U.S., in-market sales increased by 42% to reach $384 million compared to the fourth quarter of 2007, while in-market sales outside the U.S. increased by 27% to $211 million.
Market Data 
Markets 
AI
